PKD2 and neoplasm: In cholangiocarcinoma (CCA) lnc-PKD2–2-3 increased CD44, CD133 and OCT4 expression as well as the CD44 + CD133+ cell proportion, raised tumor sphere forming efficiency and enhanced tharapy resistance to 5-FU in TFK-1 and Huh-28 cells.